Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: Coinduction of innate and adaptive antitumor immunity and cure of disseminated disease

Cancer Research

Volumn 62, Issue 24, 2002, Pages 7254-7263

  Hill, Hank C ^a   Conway Jr , Thomas F ^b   Sabel, Michael S ^a,d   Jong, Yong S ^c   Mathiowitz, Edith ^c   Bankert, Richard B ^b   Egilmez, Nejat K ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; MICROSPHERE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; LUNG METASTASIS; LYMPHOCYTE SUBPOPULATION; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY; TUMOR RECURRENCE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG SYNERGISM; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-12; LUNG NEOPLASMS; LYMPHOCYTE SUBSETS; MALE; MICE; MICE, INBRED BALB C; MICROSPHERES; NEOADJUVANT THERAPY; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037115541     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Parmiani, G., Rodolfo, M., and Melani, C. Immunological gene therapy with ex vivo gene-modified tumor cells: A critique and a reappraisal. Hum. Gene Ther., 11: 1269-1275, 2000.
2. Sogn, J. A. Tumor immunology: The glass is half full. Immunity, 9: 757-763, 1998.
3. Soiffer, R., Lynch, T., Mihm, M., Jung, K., Rhuda, C., Schmollinger, J. C., Hodi, F. S., Liebster, L., Lam, P., Mentzer, S., Singer, S., Tanabe, K. K., Cosimi, A. B., Duda, R., Sober, A., Bhan, A., Daley, J., Neuberg, D., Parry, G., Rokovich, J., Richards, L., Drayer, J., Berns, A., Clift, S., Cohen, L. K., Mulligan, R. C., and Dranoff, G. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA, 95: 13141-13146, 1998.
4. Sun, Y., Jurgovsky, K., Möller, P., Alijagic, S., Dorbic, T., Georgieva, J., Wittig, B., and Schadendorf, D. Vaccination with IL-12 gene-modified autologous melanoma cells: Preclinical results and a first clinical Phase I study. Gene Ther., 5: 481-490, 1998.
5. Perez-Diez, A., Spiess, P. J., Restifo, N. P., Matzinger, P., and Marincola, F. M. Intensity of the vaccine-elicited immune response determines tumor clearance. J. Immunol., 168: 338-347, 2002.
6. Colombo, M. P., and Forni, G. Immunotherapy 1: Cytokine gene transfer strategies. Cancer Metastasis Rev., 16: 421-432, 1997.
7. Zinkemagel, R. M. Immunity against solid tumors? Int. J. Cancer, 93: 1-5, 2001.
8. Ochsenbein, A. F., Klenerman, P., Karrer, U., Ludewig, B., Pericin, M., Hengartner, H., and Zinkemagel, R. M. Immune surveillance against a solid tumor fails because of immunological ignorance. Prec. Natl. Acad. Sci. USA, 96: 2233-2238, 1999.
9. Egilmez, N. K., Jong, Y. S., Sabel, M. S., Jacob, J. S., Mathiowitz, E., and Bankert, R. B. In situ tumor vaccination with interleukin-12 encapsulated biodegradable microspheres: Induction of tumor regression and potent antitumor immunity. Cancer Res., 60: 3832-3837, 2000.
10. Cavallo, F., Signorelli, P., Giovarelli, M., Musiani, P., Modesti, A., Brunda, M. J., Colombo, M. P., and Forni, G. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J. Natl. Cancer Inst. (Bethesda), 89: 1049-1058, 1997.
11. Kiessling, R., Wasserman, K., Horiguchi, S., Kono, K., Sjöberg, J., Pisa, P., and Petersson, M. Tumor-induced immune dysfunction. Cancer Immunol. Immunother., 48: 353-362, 1999.
12. Hsieh, C. L., Chen, D. S., and Hwang, L. H. Tumor-induced immunosuppression: A barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine. Hum. Gene Ther., 11: 681-692, 2000.
13. Simon, R. M., Steinberg, S. M., Hamilton, M., Hildesheim, A., Khleif, S., Kwak, L. W., Mackall, C. L., Schlom, J., Topalian, S. L., and Berzofsky, J. A. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J. Clin. Oncol., 19: 1848-1854, 2001.
14. Bendandi, M., Gocke, C. D., Kobrin, C. B., Benko, F. A., Sternas, L. A., Pennington, R., Watson, T. M., Reynolds, C. W., Gause, B. L., Duffey, P. L., Jaffe, E. S., Creekmere, S. P., Longo, D. L., and Kwak, L. W. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med., 5: 1171-1177, 1999.
15. Sabel, M. S., Hill, H., Jong, Y. S., Mathiowitz, E., Bankert, R. B., and Egilmez, N. K. Neoadjuvant therapy with Interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases. Surgery, 130: 470-478, 2001.
16. Wexler, H. Accurate identification of experimental pulmonary metastases. J. Natl. Cancer Inst. (Bethesda), 36: 641-645, 1966.
17. Tanaka, T., Kitamura, F., Nagasaka, Y., Kuida, K., Suwa, H., and Miyasaka, M. Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor β chain monoclonal antibody in mice. J. Exp. Med., 178: 1103-1107, 1993.
18. Mumberg, D., Monach, P. A., Wanderling, S., Philip, M., Tolendano, A. Y., Schreiber, R. D., and Schreiber, H. CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl. Acad. Sci. USA, 96: 8633-8638, 1999.
19. Bloor, A. G., Jou, Y., Hoeplinger, C., Gartner, J. E., Mayers, G. L., and Bankert, R. B. Hapten-specific B cell repertoire probed by hybridoma technology: Selection and characterization of representative clonotypes from the antibody-forming cell pool. J. Immunol., 128: 1443-1449, 1982.
20. Wigginton, J. M., Park, J. W., Gruys, M. E., Young, H. A., Jorcyk, C. L., Back, T. C., Brunda, M. J., Strieter, R. M., Ward, J., Green, J. E., and Wiltrout, R. H. Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: Induction of local T cell infiltration. Fas/Fas ligand gene expression, and mammary epithelial apoptosis. J. Immunol., 166: 1156-1168, 2001.
21. Janssen, R. A. J., Mulder, N. H., The, T. H., and de Leij, L. The immunobiological effects of interleukin-2 in vivo. Cancer Immunol. Immunother., 39: 207-216, 1994.
22. Wigginton, J. M., Komschlies, K. L., Back, T. C., Franco, J. L., Brunda, M. J., and Wiltrout, R. H. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J. Natl. Cancer Inst. (Bethesda), 88: 38-43, 1996.
23. Trinchieri, G. Interleukin-12: A cytokine at the interface of inflammation and immunity. Adv. Immunol., 70: 83-243, 1998.
24. Egilmez, N. K., Jong, Y. S., Hess, S. D., Jacob, J. S., Mathiowitz, E., and Bankert, R. B. Cytokines delivered by biodegradable microspheres promote effective suppression of human tumors by human peripheral blood lymphocytes in the SCID/Winn model. J. Immunother., 23: 190-195, 2000.
25. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
26. Smyth, M. J., Taniguchi, M., and Street, S. E. A. The anti-tumor activity of IL-12: Mechanisms of innate immunity that are model and dose dependent. J. Immunol., 165: 2665-2670, 2000.
27. Gee, M. S., Koch, C. J., Evans, S. M., Jenkins, W. T., Pletcher, C. H., Jr., Moore, J. S., Koblish, H. K., Lee, J., Lord, E. M., Trinchieri, G., and Lee, W. M. F. Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12. Cancer Res., 59: 4882-4889, 1999.
28. Fujiwara, H., and Hamaoka, T. Coordination of chemokine and adhesion systems in intratumoral T cell migration responsible for the induction of tumor regression. Int. Immunopharm., 1: 613-623, 2001.
29. Gaudernack, G., and Gjertsen, M. K. Combination of GM-CSF with antitumour vaccine strategies. Eur. J. Cancer, 35: S33-S35, 1999.
30. Aruga, A., Tanigawa, K., Aruga, E., Yu, H., and Chang, A. E. Enhanced adjuvant effect of granulocyte-macrophage colony-stimulating factor plus interleukin-12 compared with either alone in vaccine-induced tumor immunity. Cancer Gene Ther., 6: 89-95, 1999.
31. Refaeli, Y., Van Parijs, L., London, C. A., Tschopp, J., and Abbas, A. K. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity, 8: 615-623, 1998.
32. Ku, C. C., Murakami, M., Sakamoto, A., Kappler, J., and Marrack, P. Control of homeostasis of CD8 memory T cells by opposing cytokines. Science (Wash. DC), 288: 675-678, 2000.
33. Cohen, P. A., Peng, L., Plautz, G. E., Kim, J. A., Weng, D. E., and Shu, S. CD4+ T Cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit. Rev. Immunol., 20: 17-56, 2000.
34. Smyth, M. J., Crowe, N. Y., Hayakawa, Y., Takeda, K., Yagita, H., and Godfrey, D. I. NKT cells - Conductors of tumor immunity? Curr. Opin. Immunol., 14: 165-171, 2002.
35. Takeda, K., Hayakawa, Y., Atsuta, M., Hong, S., Van Kaer, L., Kobayashi, K., Ito, M., Yagita, H., and Okumura, K. Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12. Int. Immunol., 12: 909-914, 2000.
36. Blieden, T. M., McAdam, A. J., Frelinger, J. G., and Lord, E. M. Mechanism of cytolytic T lymphocyte killing of a low class I-expressing tumor. J. Immunol., 147: 1433-1438, 1991.
37. Le, H. N., Lee, N. C., Tsung, K., and Norton, J. A. Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12. J Immunol., 167: 6765-6772, 2001.
38. Pham-Nguyen, K. B., Yang, W., Saxena, R., Thung, S. N., Woo, S. L. C., and Chen, S-H. Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma. Int. J. Cancer, 81: 813-819, 1999.
39. Grufman, P., and Kärre, K. Innate and adaptive immunity to tumors: IL-12 is required for optimal responses. Eur. J. Immunol., 30: 1088-1093, 2000.